Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
Authors
Andreas Pinter (ORCID: https://orcid.org/0000-0002-1330-1502)
Simone Rubant
Leonidas Drogaris
Antonio Costanzo (ORCID: https://orcid.org/0000-0001-9697-2557)
Michael Bukhalo
Lev Pavlovsky (ORCID: https://orcid.org/0000-0001-8400-9587)
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
Andreas Pinter, Simone Rubant, Leonidas Drogaris, Antonio Costanzo et al.
Citations
2 citations
Journal
Dermatology and Therapy
Topics
Psoriasis: Treatment and Pathogenesis
Field-Weighted Citation Impact (FWCI)
0.48
article
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
Andreas Pinter, Simone Rubant, Leonidas Drogaris, Antonio Costanzo, Michael Bukhalo, Lev Pavlovsky, Georgios Kokolakis, Richard Bruce Warren, Diamant Thaçi, Vassilis Stakias, Ahmed M. Soliman, Yu‐Huei Huang, Nadia Ibrahim, Yanbing Zheng, Neil J. Korman
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
Dermatology and TherapyVol. 14(12)
Institutions
Goethe University Frankfurt (DE), Humanitas University (IT), Tel Aviv University (IL), Chang Gung University (TW), University Hospitals of Cleveland (US), Manchester Academic Health Science Centre (GB), Rabin Medical Center (IL), Salford Royal NHS Foundation Trust (GB), AbbVie (United States) (US), Chang Gung Memorial Hospital (TW), Humboldt-Universität zu Berlin (DE), Manchester University NHS Foundation Trust (GB), Arlington Dermatology (US), AbbVie (Germany) (DE), University Hospital Frankfurt (DE), NIHR Manchester Biomedical Research Centre (GB), IRCCS Humanitas Research Hospital (IT), Case Western Reserve University (US), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE), University of Lübeck (DE)